Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Zastumotide (Primary) ; AS15
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2018 as reported by ClinicalTrials.gov record.
- 02 May 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.